# 1. Financial Performance ## A. Key Figures * EBITDA Margin: 9.80% FY23–24 · 23.65% FY24 · 21.40% FY24–25 · ~20% current FY25 · ~20.75% TTM FY26 * PAT Margin: 5.23% FY23–24 · 14.13% FY24–25 ## B. Revenue Growth * **Accelerating Top-Line Momentum:** Revenue trajectory shows strong double-digit growth in FY25, with performance significantly outpacing prior year despite lower TTM revenue base. * **Near-Term Visibility:** Company on track to achieve **₹65–70 Cr** in FY25, reflecting robust demand and execution capability. ## C. EBITDA & PAT Margins * **Sharp Margin Expansion:** EBITDA margins more than doubled in FY24, driven by **favorable raw material costs** and shift toward **commercialization of registered products**. * **Pricing Power & Cost Leverage:** Sustained selling prices amid declining Paracetamol input costs (~₹400/kg) enabled margin expansion even with flat revenues. * **Improved Profitability Trend:** PAT margin rose sharply to 35% in FY24–25, reflecting operating leverage and better cost control. ## D. Balance Sheet Strength * **Deleveraging Underway:** Raised capital partially used to repay secured loans, improving balance sheet resilience ahead of expansion. * **Offshore Operations Timing:** Nigerian business activities will not impact consolidated books until FY27, deferring balance sheet recognition. ## E. Cash Flow & Working Capital * **Inventory Build-Up Strategic:** Inventory days surged from 115 to 347 due to **bulk procurement for production efficiency**, **complex product composition**, and **discount optimization**. * **Working Capital Pressure:** Shift from loan-license model to full material ownership has increased inventory burden despite stable sales. * **Tighter Payables & Receivables:** Days payable cut to 112 (from 360), driven by early payment discounts; MSME norms also reduced DSO, improving cash conversion. * **Capital Allocation:** **₹11 Cr** earmarked for working capital to support projected revenue growth over next 1–2 years. --- # 2. Export & Geography Mix ## A. Key Figures * Export Revenue: 63.78% of total sales (FY24) · ₹35.83 Cr total revenue (FY24) * **Merchant Export Target:** **50% increase** targeted, contributing **10–15%** of total revenue by FY26–27 * Nigeria Revenue: **~0.5%** of total (current), projected to reach **5–10%** by FY27 * **Direct Export (Owned Brands):** **<1% to 1%** of total sales ## B. Merchant Export Strategy * **Strategic Growth Vector:** Merchant exports targeted for strong expansion, with potential to add **mid-teens percentage points** to revenue mix by FY27. * **High-Margin Product Rollout:** Initial Nigeria product launch includes select high-margin offerings, supporting an estimated **40–50% EBITDA margin** on associated sales. ## C. Nigeria Market Entry * **JV-Led Market Access:** Partnership with **Eurosun Pharmaceuticals**—a seasoned merchant exporter with 5+ years in Nigeria—enables rapid market entry with **over 20 Curis products**. * **Controlled Collaboration:** Curis retains **manufacturing quality control and brand ownership**; Eurosun holds marketing rights, with selective brand co-ownership. * **Experienced Partner:** Eurosun, led by Mr. Harivandan with **15+ years in business development**, operates across multiple African and Latin American markets. ## D. Africa Regional Expansion * **Phased Geographic Rollout:** Initial focus on Nigeria and Kenya, with **own-brand launch planned in Ghana by 2027–2028**. * **Kenya as Key Market:** Currently contributes **20–30% of sales**, with plans to increase share via direct brand promotion. * **Multi-Country Footprint:** Partner Eurosun has existing presence in **Ghana, Kenya, Congo, and Latin America**, enabling future scalability beyond Nigeria. --- # 3. Product & Segment Performance ## A. Key Figures * **Contract Manufacturing Growth (Exports):** **20–25%** YoY (current) → **30–40%** targeted next fiscal * **Injectables Contribution:** **30–40%** of current revenue from key clients; **40–50%** at Centurion, **3–4%** at Eurosun Nigeria ## B. Contract Manufacturing * **Strategic Shift:** Discontinued low-margin **job work and loan license** models (<1% of sales) to focus on higher-value manufacturing. * **Export-Led Growth:** Prioritizing **merchant export contract manufacturing** with targeted acceleration to 30–40% annual growth. * **Domestic Plateau:** Domestic contract manufacturing will be stabilized but not expanded due to **fixed-margin constraints** from clients. * **JV Execution Model:** In joint ventures, **Curis leads manufacturing and development**, while partners like Eurosun handle marketing. ## C. Own Brand Strategy * **Margin Transformation Playbook:** Own brand to become **exclusive focus post-IPO**, targeting high-margin global expansion with local offices and sales teams. * **Scalable Margin Upside:** Own brand carries **very high EBITDA margins**, with Rantac example showing **300–400% MRP markup** over cost. * **Portfolio & Brand Leverage:** Established brands boost entire portfolio pricing power; company aims for **3,000 products** to support global rollout. * **Revenue Mix Shift:** Strategic pivot from <1% to **30% own-brand revenue by FY28–29**, expected to lift overall profitability. ## D. Injectable Product Pipeline * **Near-Term Commercial Catalyst:** Injectable facility to produce **vials, ampoules, and ready-mix (PMS)**, with launch tied to regulatory clearance. * **Built-In Demand:** **Existing clients already derive 30–40% of revenue from injectables**, enabling immediate uptake and **Year 1 revenue generation**. * **Market Access via Clients:** Strong injectables presence at **Centurion (40–50 CR)** and **Eurosun Nigeria (3–4 CR)** validates demand and distribution leverage. ## E. Oncology & Beta-Lactam Focus * **Strategic Expansion:** Targeting **oncology manufacturing** in Africa (Nigeria, Ghana, Kenya), where **no local production exists**, filling critical gaps. * **Client-Driven Pipeline:** Demand validated by key clients like **Venus, Angel, and Centurion** with established oncology sales. --- # 4. Manufacturing & Capacity ## A. Key Figures * **Capex (Injectables):** **₹50–55 Cr** (includes two years of pre-commercial expenses) * Capex (Factory Upgrades): ₹2.61 Cr (testing columns, energy-efficient filters, epoxy flooring) * **Land Requirement:** **4,000–5,000 sqm** for injectables facility; planned acquisition of **5,000 sqm** at GIDC * **Land Cost Advantage:** **Significantly lower** vs. other Ahmedabad areas; **installment-based payment** enabled by government incentives ## B. Facility Expansion * **Strategic Expansion into Injectables:** Entry into injectable manufacturing planned to capture high-potential markets like Nigeria, with full operations expected in **2 to 3 years**. * **Phased, Non-Disruptive Growth:** New building to be constructed adjacent to current facility to expand warehousing, QC, and stability testing without interrupting ongoing production. ## C. Land & Capex Plan * **Self-Funded, Incentivized Land Acquisition:** Land to be acquired in Sanand GIDC—leveraging lower costs and government incentives—for future injectables and support infrastructure. * **Efficiency & Compliance Investments:** Upgrades include testing columns to accelerate throughput and energy-saving air filters, while **epoxy flooring** ensures compliance with audit standards for African export markets like Tanzania and Ghana. ## D. GIDC Infrastructure * **Strategic Location in Industrial Hub:** Manufacturing unit located in **Sanand GIDC**, a 17,000-hectare dedicated industrial zone hosting global firms (Tata Nano, Nestle, Nivea), operated by GIDC. --- # 5. Regulatory & Registration Progress ## A. Key Figures * **Product Registrations:** **Over 100** registered in FY24 (**50–70** commercially active) * **Investment Allocation:** **15%** allocated to GC for registration purposes ## B. Product Approvals * **Strategic Market Expansion:** Focus on own-brand registration in Nigeria for FY25–26, followed by Kenya; process may span **1 to 5 years** due to regulatory timelines. * **Progress Despite Delays:** Registration momentum resumed post-COVID, following WHO certification in 2018 and initiation of filings in 2019 after pandemic-related setbacks. * **Commercial Uptake Improving:** Surge in order frequency and volume reflects growing commercialization of recently registered products, a shift from earlier small, sporadic orders. ## C. Country Certifications * **Global Access Secured:** WHO GMP accreditation since 2017 enables exports to **over 26 countries**; no regulatory violations reported. * **Diversified Approval Portfolio:** Holds active licenses in Nigeria (NAFTEC), Kenya (PPC), Philippines (FDA), and Yemen, all renewed every 3–5 years. * **Ghana Entry Imminent:** Contract manufacturing registration underway with audit scheduled for March–April; certification expected **2–3 months post-audit**, valid 3–4 years. ## D. Stability Testing Timeline * **Development Pace Constrained:** Annual product development progress limited to **20–30%** due to mandatory 6-month stability testing and batch/formulation requirements. ## E. Audit Readiness * **Foundational Compliance:** Manufacturing license secured in September 2017, forming basis for subsequent certifications. --- # 6. Risks & Regulatory Hurdles ## A. Key Figures * **Inventory Period:** **347 days** (current) vs. normal **90–100 days** * **Market Entry Cost (Nigeria):** **$50,000–$70,000** for 10 products ($5,000/product; $20,000 country fee) * **Paracetamol Price Surge:** **₹190–200/kg** (pre-COVID) → **₹800–900/kg** (2022) ## B. Product Registration Delays * **Prolonged Market Access:** Entry into regulated markets like Nigeria and Myanmar requires **multi-year regulatory and company registration processes**, creating significant time and capital barriers. * **Operational Hurdle:** Full market entry is contingent on completion of both **entity-level audits and product-specific approvals**, delaying revenue generation. ## C. Inventory Cycle Risk * **Elevated Inventory Levels:** Current inventory holding period is **nearly 3.5x above normal**, signaling either strategic stockpiling or reduced off-take due to prior input cost volatility. * **Demand Sensitivity:** Sharp rise in paracetamol prices led to **customer destocking behavior**, with orders limited to immediate needs amid margin pressure. ## D. Market Entry Costs * **High Upfront Investment:** Entering Nigeria demands **substantial pre-revenue spending**, including registration, audits, and compliance, amounting to **$50K–$70K for a 10-product portfolio**. ## E. Funding Dependency * **Self-Funded Expansion:** Growth initiatives will be financed entirely through **internal accruals**, with no plans for external capital raises. * **Investor Support Critical:** Despite past and ongoing execution risks, management underscores **investor funding as essential for scaling operations**. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth (FY26):** **20–25%** projected * PAT Growth (FY26): 20–30% projected (from base of ₹6.1 Cr) * **EBITDA Margin (FY26):** **~22%** projected (**~10% pts increase**) * **Revenue (FY27):** **₹55–60 Cr** projected * **Long-Term Goal:** **2–3x valuation** in **3–4 years** ## B. FY26 Revenue & Profit Outlook * **Confident Growth Trajectory:** Revenue and PAT both on track for strong double-digit expansion, supported by strategic shift to **higher-margin products** and post-September momentum. * **Margin Re-rating Underway:** EBITDA margin expected to more than double, driven by product mix improvement and operational leverage. ## C. Strategic Expansion & Long-Term Vision * **Scaling Ambition:** Target to become a **top 50–100 company** in India within 3–4 years, with revenue potentially reaching **80+ crores** by FY27 under current growth assumptions. * **P&L Impact from FY27:** Partnership benefits to reflect in financials, with **moderate top-line growth** but **meaningful margin expansion** expected over next 2–3 years. * **Capex Discipline:** FY27 investment planned at **prior-year levels or slightly higher**, aligning with phased scaling. ## D. Brand Development Roadmap * **Injectables Launch in 2–3 Years:** Strategic focus on **own marketing, brand registration, and merchant exports** as key enablers of future value creation.